Oncotarget

Research Papers:

Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells

Daniele Tibullo, Ignazio Barbagallo, Cesarina Giallongo, Luca Vanella, Concetta Conticello, Alessandra Romano, Salvatore Saccone, Justyna Godos, Francesco Di Raimondo and Giovanni Li Volti _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:28868-28880. https://doi.org/10.18632/oncotarget.7563

Metrics: PDF 1325 views  |   HTML 1821 views  |   ?  


Abstract

Daniele Tibullo1,3,*, Ignazio Barbagallo2,*, Cesarina Giallongo1, Luca Vanella2, Concetta Conticello1, Alessandra Romano1, Salvatore Saccone3, Justyna Godos2, Francesco Di Raimondo1, Giovanni Li Volti4,5

1Division of Haematology, AOU “Policlinico - Vittorio Emanuele”, University of Catania, Catania, Italy

2Department of Drug Sciences, University of Catania, Catania, Italy

3Department of Biological, Geological and Environmental Sciences, University of Catania, Catania, Italy

4Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy

5EuroMediterranean Institute of Science and Technology, Palermo, Italy

*These authors have contributed equally to this work

Correspondence to:

Giovanni Li Volti, email: livolti@unict.it

Keywords: heme oxygenase, oxidative stress, multiple myeloma, endoplasmic reticulum stress, genomic instability

Received: November 17, 2015     Accepted: January 20, 2016     Published: February 22, 2016

ABSTRACT

Multiple myeloma (MM) is a clonal B-cell malignancy characterized by an accumulation of clonal plasma cells in the bone marrow leading to bone destruction and bone marrow failure. Several molecular mechanisms underlie chemoresistance among which heme oxygenase-1 (HO-1) could play a major role. The aim of the present research was to evaluate the impact of HO-1 in MM following bortezomib (BTZ) treatment and how HO-1 is implicated in the mechanisms of chemoresistance. MM cells were treated for 24h with BTZ (15 nM), a boronic acid dipeptide inhibitor of the 26S proteasome used in the treatment of patients with MM as first-line therapy. We evaluated cell viability, reactive oxygen species (ROS) formation, endoplasmic reticulum (ER) stress, HO-1 expression and compartmentalization and cellular genetic instability. Results showed that BTZ significantly reduced cell viability in different MM cell lines and induced ER-stress and ROS formation. Concomitantly, we observed a significant overexpression of both HO-1 gene and protein levels. This effect was abolished by concomitant treatment with 4-phenybutirric acid, a molecular chaperone, which is known to reduce ER-stress. Surprisingly, inhibition of HO activity with SnMP (10μM) failed to increase BTZ sensitivity in MM cells whereas inhibition of HO-1 nuclear translocation by E64d, a cysteine protease inhibitor, increased sensitivity to BTZ and decreased genetic instability as measured by cytokinesis-block micronucleus assay. In conclusion, our data suggest that BTZ sensitivity depends on HO-1 nuclear compartmentalization and not on its enzymatic activity and this finding may represent an important tool to overcome BTZ chemoresistance in MM patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7563